The bacterium Clostridioides difficile is named “difficult” for a reason. Originally it was hard to grow in the lab, and now ...

Study finds underutilization of fidaxomicin, a recommended treatment for C. diff infection, despite increased use in hospitals.

An mRNA vaccine that targets several aspects of C. difficile’s ability to cause severe disease prevented major symptoms and death in mice.

Scientists have gained fresh insights into the prevention of the superbug Clostridium difficile (C. difficile) thanks to a new study. C. difficile is found in the environment but is most common in ...

Have a weakened immune system due to cancer, organ transplant, or treatment with immunosuppressive drugs (such as people with inflammatory bowel disease or autoimmune conditions). Have close contact ...

In fact, C. diff infections often spring up because the bacteria take advantage of a weakened microbiome following treatment with antibiotics for other diseases. “Treatment of C. difficile ...

When those bacteria die — for instance, as a result of antibiotic treatment for an unrelated infection — the large intestine ...

Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US ...

There are about 500,000 cases of C. difficile each year; about one in six people with the infection will see it come back within two to eight weeks of the initial infection. “Treatment of C.

Therefore, a two-step diagnostic algorithm with a rapid highly sensitive screening method to identify positive samples, to be confirmed by gold standard, should be strongly recommended. Some ...

Against that backdrop, the shortlisting of Astellas Pharma's C. diff treatment Dificlir (fidaxomicin) for the UK Prix Galien Innovative Product Award, reflects the critical need for additional ...